- Compositions to treat Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis
- Includes naturally-occurring compounds (+)-Puupehenone and (+)-ent-Chromazonarol
- Can inhibit both growth and toxin production of C. difficile, the growth and survival of replicating and dormant M. tuberculosis, and the the growth of E. faecalis
The invention developed by researchers at the University of Central Florida and the University of Toledo consists of new compound derivatives to treat Clostridioides difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis) infections. The derivatives are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, both naturally occurring products. The new compound derivatives 1) inhibit both the growth and toxin production of C. difficile and 2) inhibit the growth and survival of both replicating and dormant M. tuberculosis in vitro.
The research team is seeking partners for licensing and/or research collaboration.
- Modified compounds have higher efficacy in vitro
- Derived from an easier to synthesize pre-cursor compound
- Treatment of C. difficile, E. faecalis, or M. tuberculosis infections in patients